checkAd

     185  0 Kommentare Codexis to Present Update on ECO Synthesis Platform at TIDES Europe

    REDWOOD CITY, Calif., Oct. 27, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced a presentation highlighting the role of an enzymatic approach to support RNA-based therapeutics manufacturing at the TIDES Europe annual meeting taking place in Amsterdam, Netherlands and virtually October 30-November 1, 2023.

    During the presentation, Codexis will showcase how engineered enzymes can complement traditional chemical synthesis methods by addressing scalability, cost and waste challenges associated with commercial-scale production. The Company will also showcase its technical progress on its Enzyme-Catalyzed Oligonucleotide (ECO) Synthesis technology platform, being developed to enable an enzymatic route of nucleic acid synthesis. The presentation will be held live and virtually on Wednesday, November 1, 2023. The Company will make a video recap of the TIDES Europe presentation available on its website following the conclusion of the meeting.

    Presentation Details

    Title: Revolutionizing Nucleic Acid Synthesis with Engineered Enzymes
    Date: Wednesday, November 1, 2023
    Time: 1:25 pm – 1:55 pm Central European Time (CET)
    Location: RAI Amsterdam, Amsterdam, Netherlands

    About the ECO Synthesis Platform
    Ribonucleic acid (RNA) as a therapeutic modality has gained tremendous traction in recent years with the growing number of messenger RNA (mRNA) vaccines and small interfering RNA (siRNA) candidates advancing in clinical studies. However, large-scale production of RNAi therapeutics using traditional chemical synthesis faces complex challenges in nucleic acids quality and quantity, as well as overall economics. With over 450 RNA interference (RNAi) therapies currently in clinical development, including more than 40 assets in Phase 2 and Phase 3 clinical trials targeting disease indications impacting millions of patients, RNAi therapeutic demand is projected to outpace current production capabilities by the end of the decade. Codexis’ proprietary ECO Synthesis technology platform is being designed to address these scalability and cost limitations by potentially enabling the commercial-scale manufacture of RNAi therapeutics through an enzymatic route. The Company is on track to demonstrate gram-scale synthesis by the end of 2023, where it will demonstrate the preparative-scale manufacture of an oligonucleotide, composed of the modified nucleotide building blocks typically used in RNAi therapeutics, under process-like conditions.

    Seite 1 von 3



    globenewswire
    0 Follower
    Autor folgen

    Verfasst von globenewswire
    Codexis to Present Update on ECO Synthesis Platform at TIDES Europe REDWOOD CITY, Calif., Oct. 27, 2023 (GLOBE NEWSWIRE) - Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced a presentation highlighting the role of an enzymatic approach to support RNA-based therapeutics …